Philips Launches QuickClear Mechanical Thrombectomy System for Blood Clot Removal Published: Sept 25,2020 | Tags: Philips, Launches, QuickClear Mechanical Thrombectomy System, Blood Clot Removal 2. BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate -274 Study for Patients with High-Risk Muscle-Invasive Urothelial Carcinoma Published: Sept 25,2020 | Tags: BMS, Reports, Results, Opdivo, (nivolumab), P-III, CheckMate […]Read More
Shots: Royal Philips has expanded its peripheral vascular disease portfolio with the launch of the QuickClear mechanical thrombectomy system. The system features an all-in-one aspiration pump and catheter for the removal of blood clots from the vessels of the peripheral arterial and venous systems The system eliminates the requirement for capital equipment or expensive accessories, […]Read More
Shots: The P-III CheckMate -274 study involves assessing of Opdivo vs PBO in 709 patients in a ratio (1:1) with muscle-invasive urothelial cancer at a high risk of recurrence after radical surgery for up to 1yr. The study met its 1EPs of DFS in both all randomized patients and in patients whose tumor cells express […]Read More
Shots: Medtronic enrolls the first patient in the ALLEVIATE-HF clinical trial assessing the ability of its Reveal LINQ ICM in identifying patients at high risk of worsening HF. The study will enroll ~300 patients at up to 30 sites across the US for a minimum of 7mos.and up to 3yrs. The focus of the study […]Read More
Shots: Health Canada, under (NOC/c) policy, has granted market authorization to Polivy + bendamustine and rituximab (BR) for six 21-day cycles in adult patients with r/r DLBCL, who are not eligible for ASCT and prior treated with at least one therapy The approval is based on P-I/II GO29365 study assessing Polivy + BR vs BR […]Read More
Shots: Novavax has initiated a P-III study assessing the efficacy, safety, and immunogenicity of NVX-CoV2373 vs PBO in Matrix-M in up to 10,000 individuals aged 18-84yrs. with/out relevant comorbidities, over the next 4-6wks. Half the participants will receive two IM injections of a vaccine comprising 5µg of protein antigen with 50µg Matrix‑M adjuvant, administered 21 […]Read More
Shots: Accord launches Zercepac as s a biosimilar referencing Herceptin in the UK, following the EC’s approval in Jul’2020. The EC’s approval is based on a series of robust studies including comparative quality studies, pre/ clinical studies. The results confirmed the Zercepac’s bio-similarity, demonstrating comparable efficacy and safety to the Herceptin Zercepac is the first […]Read More
To remain successful in the oncology market, change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However, despite robust levels of pipeline activity, oncology remains a challenging area for research […]Read More
Shots: The companies have expanded their clinical trial collaboration and supply agreement for IDE196 and crizotinib. The study will evaluate combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including MUM, skin melanoma, lung cancer, and colorectal cancer The two global companies have established JDC and there will be joint decision […]Read More
Shots: The two P-III studies (ENHANCE-1 & ENHANCE-2) will assess the efficacy and safety of nebulized ensifentrine (3mg, bid) as monothx. and added onto a single bronchodilator either a LAMA/ LABA vs PBO in ~800 patients with mod. to sev. COPD at sites primarily in the US and EU for 24wks. & 48wks. respectively The […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
